Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $10.80.

A number of research firms have weighed in on RGLS. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Hedge Funds Weigh In On Regulus Therapeutics

A number of large investors have recently modified their holdings of the business. NEA Management Company LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $10,154,000. Point72 Asset Management L.P. purchased a new stake in shares of Regulus Therapeutics during the 3rd quarter worth $1,403,000. Vanguard Group Inc. grew its stake in shares of Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $352,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at about $204,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Price Performance

RGLS stock opened at $1.54 on Wednesday. The company has a market cap of $100.87 million, a price-to-earnings ratio of -1.44 and a beta of 1.61. The company has a fifty day moving average price of $1.53 and a 200 day moving average price of $1.68. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.